Fig. 2: Utilization of genomically targeted drugs and immune checkpoint inhibitors in the context of dual-matched therapy.
From: Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
The upper segment of the figure depicts the types of the immune checkpoint inhibitors implemented in the dual-matched therapy. Nivolumab and pembrolizumab are anti-PD-1 agents; atezolizumab is an anti-PD-L1 agent. The lower portion of the figure depicts individualized boxes representing the targeted agent(s) used in dual-matched therapy. The background colors of molecular targeted agent(s) denote the simultaneously administered immune checkpoint inhibitor with the same background color (blue, nivolumab; yellow, pembrolizumab; orange, atezolizumab). This tailored combination approach was customized for each patient’s unique and complex molecular profile. Patients could receive a single drug that targeted more than one biomarker (since small molecule inhibitors often have multiple targets) or more than one drug that targeted the same biomarker.
